Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lexon

This article was originally published in The Gray Sheet

Executive Summary

Diagnostics developer raises $30 mil. from Swartz Private Equity, LLC, to be drawn by Lexon as needed over the next three years. Tulsa, Oklahoma-based Lexon, which owns the exclusive worldwide rights to the Ebaf Assay blood test to screen for colon cancer and the Telomerase Assay blood test to screen for lung cancer, will use the funds for "ongoing product development and initiation of FDA clinical trials," the firm states in an Aug. 21 release. Current development efforts "are focused on expanding the battery of monoclonal antibodies for each test, producing prototype blood screening test kits, performing multiple blood tests on known cancer patients, and statistically evaluating test results for presentation to the FDA," Lexon reports
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT013785

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel